U.S., Nov. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07941492) titled 'A Trial of FHD-286 Plus Mosunetuzumab in Previously Treated Follicular Lymphoma' on Nov. 10.
Brief Summary: The goal of this clinical trial is to learn if FHD-286 in combination with mosunetuzumab is safe and tolerable for treating adults with previously treated relapsed/refractory follicular lymphoma. It will also evaluate how well the combination works and how it affects cancer-related molecular and immune markers.The main questions it aims to answer are:
* What is the maximum tolerated dose of FHD-286 when given in combination with mosunetuzumab?
* Is the combination of FHD-286 and mosunetuzumab safe and tolerable?
* How many ...